---
document_datetime: 2025-12-02 05:29:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/finlee.html
document_name: finlee.html
version: success
processing_time: 0.1104178
conversion_datetime: 2025-12-26 21:07:36.072586
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Finlee

[RSS](/en/individual-human-medicine.xml/77397)

##### Authorised

This medicine is authorised for use in the European Union

dabrafenib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Finlee](#news-on)
- [More information on Finlee](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Finlee is a cancer medicine used to treat children aged 1 year and older with glioma (a type of brain tumour). It is used together with another cancer medicine, trametinib. Finlee is only used in patients whose glioma cancer cells have a specific mutation (change) in the BRAF gene called 'BRAF V600E'.

Finlee can be used in children with:

- low-grade glioma who require systemic therapy;
- high-grade glioma when the patient has received at least one prior radiation or chemotherapy treatment.

Glioma is rare, and Finlee was designated an 'orphan medicine' (a medicine used in rare diseases) on 9 December 2020.

Finlee contains the active substance dabrafenib.

Expand section

Collapse section

## How is Finlee used?

The medicine can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in treating cancer. Before starting treatment, patients must have a test to confirm their cancer cells have BRAF V600E mutation.

Finlee is available as dispersible tablets to be taken twice a day. The tablets should be dispersed (mixed) in a small amount of water before being taken. Finlee is used together with trametinib powder for oral solution (to make up a drinkable liquid), which should be given once a day together with one of the two daily doses of Finlee.

Treatment with Finlee should continue as long as the patient benefits from it. In case of side effects the doctor may reduce or stop the treatment.

For more information about using Finlee, see the package leaflet or contact your doctor or pharmacist.

## How does Finlee work?

Glioma tumour cells with the BRAF mutation produce an abnormal form of a protein called BRAF. The abnormal BRAF protein activates another protein called MEK that is involved in stimulating cell division, resulting in uncontrolled division of cells and thus development of cancer. The active substance in Finlee, dabrafenib, works by blocking the action of the abnormal BRAF protein in patients with the BRAF mutation and thereby helps slow down the growth and spread of the cancer. The most commonly observed BRAF mutation is V600E.

## What benefits of Finlee have been shown in studies?

**Low-grade glioma**

In an ongoing study, 110 children with low-grade glioma with the BRAF V600E mutation received either Finlee combined with trametinib or chemotherapy with carboplatin and vincristine (other cancer medicines). The main measure of effectiveness was the proportion of children who responded completely or partially to treatment (whose tumour disappeared or shrank) after at least 32 weeks of treatment. Response to treatment was assessed using body scans and patients' clinical data. Treatment with Finlee and trametinib led to a response in 47% (34 out of 73) of children, compared with 11% (4 out of 37) of children receiving carboplatin and vincristine.

**High-grade glioma**

In the same ongoing study, 41 children with high-grade glioma with the BRAF V600E mutation received Finlee combined with trametinib. Of these children, 56% (23 out of 41) achieved a complete or partial response to treatment which lasted for an average of 22 months. In the treatment of high-grade glioma, Finlee was not compared with any other treatment or placebo (dummy treatment).

## What are the risks associated with Finlee?

For the full list of side effects and restrictions with Finlee, see the package leaflet.

The most common side effects with Finlee (which may affect more than 1 in 5 people) include fever, rash, headache, vomiting, tiredness, dry skin, diarrhoea, bleeding, nausea (feeling sick), dermatitis acneiform (acne-like rash), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), abdominal (belly) pain and cough.

## Why is Finlee authorised in the EU?

Children with low-grade glioma or high-grade glioma have limited treatment options. Finlee in combination with trametinib was shown to be effective in shrinking tumours in children whose cancer cells have a BRAF V600E mutation. Although safety data are limited, side effects are generally considered manageable.

The European Medicines Agency therefore decided that Finlee's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Finlee?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Finlee have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Finlee are continuously monitored. Suspected side effects reported with Finlee are carefully evaluated and any necessary action taken to protect patients.

## Other information about Finlee

Finlee received a marketing authorisation valid throughout the EU on 15 November 2023.

This overview was last updated in 11-2023.

Finlee : EPAR - Medicine overview

Reference Number: EMEA/H/C/005885

English (EN) (127.41 KB - PDF)

**First published:** 05/12/2023

[View](/en/documents/overview/finlee-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-219)

български (BG) (150.3 KB - PDF)

**First published:**

05/12/2023

[View](/bg/documents/overview/finlee-epar-medicine-overview_bg.pdf)

español (ES) (126.96 KB - PDF)

**First published:**

05/12/2023

[View](/es/documents/overview/finlee-epar-medicine-overview_es.pdf)

čeština (CS) (150.28 KB - PDF)

**First published:**

05/12/2023

[View](/cs/documents/overview/finlee-epar-medicine-overview_cs.pdf)

dansk (DA) (126.61 KB - PDF)

**First published:**

05/12/2023

[View](/da/documents/overview/finlee-epar-medicine-overview_da.pdf)

Deutsch (DE) (129.38 KB - PDF)

**First published:**

05/12/2023

[View](/de/documents/overview/finlee-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.08 KB - PDF)

**First published:**

05/12/2023

[View](/et/documents/overview/finlee-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.57 KB - PDF)

**First published:**

05/12/2023

[View](/el/documents/overview/finlee-epar-medicine-overview_el.pdf)

français (FR) (127.9 KB - PDF)

**First published:**

05/12/2023

[View](/fr/documents/overview/finlee-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.24 KB - PDF)

**First published:**

05/12/2023

[View](/hr/documents/overview/finlee-epar-medicine-overview_hr.pdf)

italiano (IT) (125.58 KB - PDF)

**First published:**

05/12/2023

[View](/it/documents/overview/finlee-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (155.15 KB - PDF)

**First published:**

05/12/2023

[View](/lv/documents/overview/finlee-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (148.14 KB - PDF)

**First published:**

05/12/2023

[View](/lt/documents/overview/finlee-epar-medicine-overview_lt.pdf)

magyar (HU) (148.72 KB - PDF)

**First published:**

05/12/2023

[View](/hu/documents/overview/finlee-epar-medicine-overview_hu.pdf)

Malti (MT) (149.48 KB - PDF)

**First published:**

05/12/2023

[View](/mt/documents/overview/finlee-epar-medicine-overview_mt.pdf)

Nederlands (NL) (127.02 KB - PDF)

**First published:**

05/12/2023

[View](/nl/documents/overview/finlee-epar-medicine-overview_nl.pdf)

polski (PL) (152.72 KB - PDF)

**First published:**

05/12/2023

[View](/pl/documents/overview/finlee-epar-medicine-overview_pl.pdf)

português (PT) (127.89 KB - PDF)

**First published:**

05/12/2023

[View](/pt/documents/overview/finlee-epar-medicine-overview_pt.pdf)

română (RO) (145.83 KB - PDF)

**First published:**

05/12/2023

[View](/ro/documents/overview/finlee-epar-medicine-overview_ro.pdf)

slovenčina (SK) (150.55 KB - PDF)

**First published:**

05/12/2023

[View](/sk/documents/overview/finlee-epar-medicine-overview_sk.pdf)

slovenščina (SL) (147.35 KB - PDF)

**First published:**

05/12/2023

[View](/sl/documents/overview/finlee-epar-medicine-overview_sl.pdf)

Suomi (FI) (124.35 KB - PDF)

**First published:**

05/12/2023

[View](/fi/documents/overview/finlee-epar-medicine-overview_fi.pdf)

svenska (SV) (124.7 KB - PDF)

**First published:**

05/12/2023

[View](/sv/documents/overview/finlee-epar-medicine-overview_sv.pdf)

Finlee : EPAR - Risk management plan

English (EN) (1.39 MB - PDF)

**First published:** 07/05/2025

[View](/en/documents/rmp/finlee-epar-risk-management-plan_en.pdf)

## Product information

Finlee : EPAR - Product Information

English (EN) (887.83 KB - PDF)

**First published:** 05/12/2023

**Last updated:** 04/11/2025

[View](/en/documents/product-information/finlee-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-508)

български (BG) (694.27 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/bg/documents/product-information/finlee-epar-product-information_bg.pdf)

español (ES) (621.47 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/es/documents/product-information/finlee-epar-product-information_es.pdf)

čeština (CS) (680.98 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/cs/documents/product-information/finlee-epar-product-information_cs.pdf)

dansk (DA) (629.54 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/da/documents/product-information/finlee-epar-product-information_da.pdf)

Deutsch (DE) (677.2 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/de/documents/product-information/finlee-epar-product-information_de.pdf)

eesti keel (ET) (583.84 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/et/documents/product-information/finlee-epar-product-information_et.pdf)

ελληνικά (EL) (730.9 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/el/documents/product-information/finlee-epar-product-information_el.pdf)

français (FR) (661.99 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/fr/documents/product-information/finlee-epar-product-information_fr.pdf)

hrvatski (HR) (692.07 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/hr/documents/product-information/finlee-epar-product-information_hr.pdf)

íslenska (IS) (633.27 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/is/documents/product-information/finlee-epar-product-information_is.pdf)

italiano (IT) (687.3 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/it/documents/product-information/finlee-epar-product-information_it.pdf)

latviešu valoda (LV) (659.72 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/lv/documents/product-information/finlee-epar-product-information_lv.pdf)

lietuvių kalba (LT) (715.56 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/lt/documents/product-information/finlee-epar-product-information_lt.pdf)

magyar (HU) (669.45 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/hu/documents/product-information/finlee-epar-product-information_hu.pdf)

Malti (MT) (712.29 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/mt/documents/product-information/finlee-epar-product-information_mt.pdf)

Nederlands (NL) (649.56 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/nl/documents/product-information/finlee-epar-product-information_nl.pdf)

norsk (NO) (624.29 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/no/documents/product-information/finlee-epar-product-information_no.pdf)

polski (PL) (705.98 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/pl/documents/product-information/finlee-epar-product-information_pl.pdf)

português (PT) (678.88 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/pt/documents/product-information/finlee-epar-product-information_pt.pdf)

română (RO) (718.05 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/ro/documents/product-information/finlee-epar-product-information_ro.pdf)

slovenčina (SK) (674.8 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/sk/documents/product-information/finlee-epar-product-information_sk.pdf)

slovenščina (SL) (684.37 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/sl/documents/product-information/finlee-epar-product-information_sl.pdf)

Suomi (FI) (639.13 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/fi/documents/product-information/finlee-epar-product-information_fi.pdf)

svenska (SV) (615.26 KB - PDF)

**First published:**

05/12/2023

**Last updated:**

03/11/2025

[View](/sv/documents/product-information/finlee-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000308071 03/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Finlee : EPAR - All Authorised Presentations

English (EN) (65.22 KB - PDF)

**First published:** 05/12/2023

[View](/en/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-290)

български (BG) (72.13 KB - PDF)

**First published:**

05/12/2023

[View](/bg/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_bg.pdf)

español (ES) (66.29 KB - PDF)

**First published:**

05/12/2023

[View](/es/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.2 KB - PDF)

**First published:**

05/12/2023

[View](/cs/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (67.74 KB - PDF)

**First published:**

05/12/2023

[View](/da/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (67.27 KB - PDF)

**First published:**

05/12/2023

[View](/de/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (64.63 KB - PDF)

**First published:**

05/12/2023

[View](/et/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (68.39 KB - PDF)

**First published:**

05/12/2023

[View](/el/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_el.pdf)

français (FR) (66.18 KB - PDF)

**First published:**

05/12/2023

[View](/fr/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.73 KB - PDF)

**First published:**

05/12/2023

[View](/hr/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (67.45 KB - PDF)

**First published:**

05/12/2023

[View](/is/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_is.pdf)

italiano (IT) (65.8 KB - PDF)

**First published:**

05/12/2023

[View](/it/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.13 KB - PDF)

**First published:**

05/12/2023

[View](/lv/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.79 KB - PDF)

**First published:**

05/12/2023

[View](/lt/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.21 KB - PDF)

**First published:**

05/12/2023

[View](/hu/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67 KB - PDF)

**First published:**

05/12/2023

[View](/mt/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (65.15 KB - PDF)

**First published:**

05/12/2023

[View](/nl/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66.47 KB - PDF)

**First published:**

05/12/2023

[View](/no/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.74 KB - PDF)

**First published:**

05/12/2023

[View](/pl/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_pl.pdf)

português (PT) (65.63 KB - PDF)

**First published:**

05/12/2023

[View](/pt/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.57 KB - PDF)

**First published:**

05/12/2023

[View](/ro/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.47 KB - PDF)

**First published:**

05/12/2023

[View](/sk/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (65.05 KB - PDF)

**First published:**

05/12/2023

[View](/sl/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (64.12 KB - PDF)

**First published:**

05/12/2023

[View](/fi/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (65.1 KB - PDF)

**First published:**

05/12/2023

[View](/sv/documents/all-authorised-presentations/finlee-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Finlee Active substance dabrafenib mesilate International non-proprietary name (INN) or common name dabrafenib Therapeutic area (MeSH) Glioma Anatomical therapeutic chemical (ATC) code L01EC02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Low-grade glioma**

Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

**High-grade glioma**

Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.

## Authorisation details

EMA product number EMEA/H/C/005885

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 14/09/2023 Marketing authorisation issued 15/11/2023 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Finlee : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.74 KB - PDF)

**First published:** 04/11/2025

[View](/en/documents/procedural-steps-after/finlee-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Finlee : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (148.41 KB - PDF)

**First published:** 04/01/2024

**Last updated:** 03/11/2025

[View](/en/documents/procedural-steps-after/finlee-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Finlee-H-C-PSUSA-00010084-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/154380/2025

English (EN) (116.5 KB - PDF)

**First published:** 07/05/2025

[View](/en/documents/scientific-conclusion/finlee-h-c-psusa-00010084-202405-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Finlee: EPAR - Paediatric investigation plan compliance statement

English (EN) (113.39 KB - PDF)

**First published:** 05/12/2023

[View](/en/documents/pip-compliance/finlee-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

## Initial marketing authorisation documents

Finlee : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000134197

English (EN) (437.31 KB - PDF)

**First published:** 05/12/2023

[View](/en/documents/orphan-maintenance-report/finlee-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Finlee : EPAR - Public Assessment Report

Reference Number: EMA/443504/2023

English (EN) (4.5 MB - PDF)

**First published:** 05/12/2023

[View](/en/documents/assessment-report/finlee-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Finlee

Adopted

Reference Number: EMA/CHMP/402638/2023

English (EN) (157.47 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-finlee_en.pdf)

#### News on Finlee

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

#### More information on Finlee

- [EU/3/20/2372 - orphan designation for treatment of glioma](/en/medicines/human/orphan-designations/eu-3-20-2372)

**This page was last updated on** 04/11/2025

## Share this page

[Back to top](#main-content)